• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Infect Dis. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019

tetano

Editor, Senior Moderator
Int J Infect Dis. 2020 Apr 22. pii: S1201-9712(20)30257-5. doi: 10.1016/j.ijid.2020.04.041. [Epub ahead of print]
Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019.


Zhu Z[SUP]1[/SUP], Cai T[SUP]2[/SUP], Fan L[SUP]3[/SUP], Lou K[SUP]4[/SUP], Hua X[SUP]5[/SUP], Huang Z[SUP]6[/SUP], Gao G[SUP]7[/SUP].

Author information




Abstract

OBJECTIVE:

To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19).
METHODS:

127 consecutive hospitalized patients with confirmed COVID-19 were enrolled in this study, and classified into non-severe and severe groups. Demographics, symptoms, underlying diseases and laboratory data were collected and assessed for predictive value.
RESULTS:

Of 127 COVID-19 patients, 16 cases (12.60%) were classified into the severe group. High level of interleukin-6 (IL-6), C-reaction protein (CRP) and hypertension were independent risk factors for the severity of COVID-19. The risk model based on IL-6, CRP and hypertension had the highest area under the receiver operator characteristic curve (AUROC). Additionally, the baseline IL-6 was positively correlated with other immune-inflammatory parameters and the dynamic change of IL-6 in the severe cases were parallel to the amelioration of the disease.
CONCLUSION:

Our study showed that high level of IL-6, CRP and hypertension were independent risk factors for assessing the severity of COVID-19. The risk model established upon IL-6, CRP and hypertension had the highest predictability in this study. Besides, IL-6 played a pivotal role in the severity of COVID-19 and had a potential value for monitoring the process of severe cases.
Copyright ? 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.



KEYWORDS:

COVID-19; Cytokine storm; IL-6; Immune-inflammatory parameters; SARS-CoV-2


PMID:32334118DOI:10.1016/j.ijid.2020.04.041
 
Back
Top